BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

1 Min Read

Jan 19 (Reuters) - BAVARIAN NORDIC A/S:

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

* OPEN-LABEL PHASE 1 TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF MVA-BN(®) BRACHYURY VACCINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below